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Introduction
Pemphigus foliaceus (PF) is an acquired autoimmune blistering disease in which the body’s
immune system produces immunoglobulin G (IgG) autoantibodies that target the
intercellular adhesion glycoprotein desmoglein-1 (dsg-1). The binding of these
autoantibodies to dsg-1, which is principally expressed in the granular layer of the
epidermis, results in the loss of intercellular connections between keratinocytes
(acantholysis) and the formation of subcorneal blisters within the epidermis. The ultimate
clinical manifestations of this process are fragile, superficial blisters and bullae of the
cutaneous surface that easily rupture to yield erosive lesions.
The pathogenic autoantibodies of PF are of the IgG4 subclass, which has been demonstrated
by their passive transfer from human sera to neonatal mice (1). These IgG4 autoantibodies
recognize antigenic epitopes located on the N-terminus of the ectodomain of dsg-1,
specifically on extracellular (EC) domains 1 and 2 (2,3). The binding of pathogenic IgG to
dsg-1 triggers the phosphorylation of p38 mitogen-activated protein kinase (MAPK) which
is thought to induce apoptosis of the affected keratinocyte (4,5,6). Although complement
component 3 (C3) deposition on direct immunofluorescence (DIF) initially suggested that it
may play a role in acantholysis in PF, both C5-deficient mice and total complement-depleted
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mice still develop subcorneal vesicles upon passive transfer of pathogenic human sera (7).
The pathogenesis of PF is covered in this issue in more detail by Valeria Aoki.
There are 2 predominant types of PF: idiopathic PF, which is found universally and occurs
sporadically, and fogo selvagem (FS), an endemic variety linked exclusively to multiple
distinct geographical areas. Other, albeit rarer, variants of PF have been described, including
pemphigus erythematosus (PE, Senear-Usher syndrome) and drug-induced PF. IgA
pemphigus and pemphigus herpetiformis (PH) have previously been described in the
literature as variants of PF, but appear to be distinct subtypes of the general pemphigus
category, both clinically and histopathologically (8).
Clinical Features
Epidemiology
The worldwide incidence and prevalence of PF is very low, making it a rare disease.
Because of the presence of endemic areas, however, these figures may vary considerably
based on the specific geographical area being studied. For instance, the incidence of PF in
Tunisia has been found to be as high as 6.7 new cases per million per year (9). In Brazil,
which has multiple foci of endemic PF, there is a region located in the state of Maso Grosso
do Sul that has a prevalence equal to approximately 3% of its population (10,11). Other
endemic areas are found within Colombia and Peru (12,13,14). The average age of non-
endemic PF symptom onset ranges from 40 to 60 years of age. FS affects a larger number of
children and young adults as symptoms usually begin during the second or third decade of
life (14). Both sporadic and endemic PF are typically seen equally in men and women and
affect those of all races and ethnicities. However, there are populations of FS that may
deviate from the norm. For example, epidemiological studies in Tunisia found the female-to-
male ratio of incidence rates to be approximately 4 to 1 (9).
Patient History
Patients usually report a history of blister formation on the skin (Fig. 1). Lesions commonly
begin on the trunk, but may also originate as localized lesions on the face or scalp. The
patient may be unaware of the blisters because they rupture very easily. In these cases, there
may only be a history of superficial sores or areas of crusting. Pain and/or a burning
sensation localized to the areas of the lesions may be noted. Unlike pemphigus vulgaris
(PV), there is typically no history of oral or other mucosal lesions. The lesions may become
widespread. Patients with the mildest form of PF may only report a history of a small,
solitary, recurrent scaly and crusty lesion of the face (Fig. 2). In these cases, it may be years
before the patient is correctly diagnosed. In cases of PE, patients report the development of
lesions in sun-exposed areas of the face, scalp, and upper chest and back—similar to the
distribution of lesions seen in lupus erythematosus (LE).
Because multiple drugs have been found to be associated with the development of PF, it is
important to thoroughly review the patient’s current medications. The most commonly
implicated drug is penicillamine, which is a chelating agent used to treat Wilson’s disease,
lead and arsenic poisoning, and severe active rheumatoid arthritis (15). Drug-associated
cases may persist or quickly clear after the offending agent is withdrawn. Various
angiotensin-converting enzyme (ACE) inhibitors have also been found to induce pemphigus.
Table 1 shows other drugs that have been associated with PF. Most of these drugs contain
thiol (-SH) functional groups in their chemical structure while others have disulfide bonds
that are cleaved during metabolism to yield thiol groups (16). PF can also be either induced
or exacerbated by exposure to ultraviolet light and ionizing radiation (17,18,19,20).
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A growing number of diseases have been associated with PF, including bullous pemphigoid,
myasthenia gravis, and other autoimmune diseases (21,22,23,24). A complete past medical
history should also be obtained to identify all pre-existing medical conditions of the patient.
PF has been associated with certain neoplasms, including B-cell lymphoma, T-cell
lymphoma, prostate cancer, and cutaneous squamous cell carcinoma (25,26,27,28).
Transition from PF to other forms of pemphigus and vice versa may occur. There have been
a few documented cases of patients with clinical, histopathological, and serological features
of PV who subsequently underwent a confirmed transition to PF (29,30). Although both are
rare, this is found more commonly than a shift from PF to PV (31).
Non-endemic PF may occur in the neonate via transplacental transit of pathogenic IgG anti-
dsg-1 autoantibodies from a mother with active disease (32,33,34). These cases are
uncommon and most neonates born of mothers with PF will not develop active disease (35).
A study of 19 mothers with documented FS revealed that all respective babies were born
with normal skin (36). Given that the sera of all of the mothers showed high titers of FS
autoantibodies, the placenta may act as an immunoadsorbant of unwanted autoantibodies
(37). Additionally, dsg-3 has been found to be present in all layers of the epidermis in
neonates, including the superficial layer, in contrast to adults, who express dsg-1
superficially and dsg-3 intermediately and basally (38). This expression of dsg-3 in the
superficial epidermis is thought to be protective against the formation of blisters induced by
PF antibodies in neonates (38).
FS, which has been extensively studied in Brazil, is thought to be triggered by an
environmental factor, perhaps from an antigen transmitted by the bite of a hematophagous
insect, in genetically-susceptible individuals. The antibodies produced against this
unidentified antigen may cross-react with dsg-1, leading to the development of FS. This
theory is based on the following observations from endemic areas of Brazil: (1) Specific
human leukocyte antigen (HLA) genes have been associated with increased FS susceptibility
(39); (2) FS displays geographic and familial clustering; (3) The families typically share a
common bedroom in poor living conditions; (4) The living dwellings tend to be infested
with blood-feeding arthropods (40); (5) A spike in FS cases occurs after the end of the rainy
season when insect breeding conditions are optimal (40); and (6) FS cases tend to decrease
as the living conditions improve in endemic areas of Brazil (10). Recent research has
focused on the study of a protein transmitted from the saliva of Simulium nigrimanum, a
type of black fly (41).
Physical Exam
The endemic and non-endemic forms of PF typically share the same clinical findings (42).
The primary lesions are flaccid, superficial vesicles and bullae of the skin. These lesions
may not be seen on examination because of their fragile and subsequent transient nature.
More often, only secondary lesions, such as shallow erosions, are seen. Scaling of these
lesions is commonly seen, representing the detachment of the overlying stratum corneum
from the area of intra-epidermal acantholysis, the stratum granulosum. Most lesions appear
on the chest, back, and shoulders (Fig. 3). On certain areas of the body such as the face and
scalp, the exudate from the erosive lesions dries quickly, leaving areas of crusting over an
erythematous base.
A common clinical finding in PF is a positive Nikolsky’s sign. This is performed by
applying shear stress to the affected skin, usually by rubbing the periphery of existing
primary or secondary lesions. If positive, this tangentially-applied force will result in the
separation of the upper epidermal layers from the underlying lower layers. This finding has
been shown to be moderately sensitive, but highly specific in diagnosing pemphigus (43).
James et al. Page 3













In its most severe form, PF can produce an exfoliative erythroderma characterized by
generalized erythema and diffuse scaling of the cutaneous surface (Fig. 4). In these cases, it
may also lead to alopecia. These patients require prompt hospitalization to prevent serious
and sometimes fatal complications from metabolic instability.
The variant PE combines features of PF and lupus erythematosus. Small, flaccid vesicles
and bullae may be seen in a butterfly-distribution on the face, involving the cheeks and nose.
Photo-distributed lesions of the scalp, and upper chest and back are also common. Ruptured
blisters reveal an erythematous base, and lesions on the face and scalp may have think,
greasy scales and yellow crusts. Many patients test positive for anti-nuclear antibodies in
their serum (44).
Unusual presentations of PF have previously been described. Several cases have been
documented of PF presenting as an acute eruption of multiple hyperpigmented and
hyperkeratotic lesions that closely resemble the appearance of seborrheic keratoses (45,46).
In cases of sporadic PF in children, patients present with the same primary and secondary
lesions, but they often have a distinct configuration having been described as arcuate,
circinate, and/or polycyclic (47).
Differential Diagnosis
The differential diagnosis of endemic and non-endemic PF includes bullous impetigo, IgA
pemphigus, PH, drug eruption, subcorneal pustular dermatosis, and lupus erythematosus. If
lesions are localized to the face or scalp with abundant scaling and yellow crusting,
seborrheic dermatitis may be considered. Papulosquamous diseases, including psoriasis,
pityriasis rubra pilaris (PRP), and drug hypersensitivity, should be additional diagnostic
considerations for patients presenting with exfoliative erythroderma.
Diagnosis
There are a variety of diagnostic studies that can be used to support clinical suspicion of PF.
Histology and direct immunofluorescence (DIF) requires tissue samples from the patient.
Biopsy for DIF should be taken from perilesional skin—normal-appearing skin immediately
adjacent to a lesion—since inflamed and blistered skin may lead to the destruction of
immune deposits and result in a false-negative study (48). Indirect immunofluorescence
(IIF) and enzyme-linked immunosorbent assay (ELISA) studies require patient serum.
Ultimately, the diagnosis of PF is based on three criteria: (1) The overall clinical picture,
including patient history and physical exam; (2) The histopathological findings of the
biopsy; and (3) The presence of autoantibodies as detected by direct and indirect
immunofluorescent studies. Neither one of these alone is diagnostic of PF.
Histopathology
The earliest pre-acantholytic findings in PF are the formation of vacuoles within the
intercellular spaces of the granular and/or upper spinous layers of the epidermis (49).
Eosinophilic spongiosis of the epidermis may also be seen (50). As PF lesions progress, the
vacuoles become larger and eventually lead to subcorneal blister formation within the upper
epidermis (Fig. 5). There are variable amounts of acantholytic keratinocytes, neutrophils,
and fibrin within the blisters (51). Older PF lesions show evidence of chronic inflammation,
including papillomatosis, acanthosis, hyperkeratosis, parakeratosis, and follicular plugging.
Keratinocytes of the granular layer display dyskeratotic changes. There is an increase in
pigment formation of basal melanocytes. The capillaries of the papillary dermis become
dilated. Upper dermal edema may be present to varying degrees. An inflammatory infiltrate
composed of small amounts of neutrophils, eosinophils, and lymphocytes may be present in
a variable distribution (52).
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DIF is a special immunostaining procedure that is used to detect antibody and complement
deposition within the tissue sample. For diagnosis of any pemphigus disease, its sensitivity
has been found to range from 80–95% (53). DIF becomes positive earlier in the course of
disease than IIF and is thus, considered slightly more reliable in detecting the initial
presentations of PF (54). PF shows a DIF pattern characterized by fluorescent staining
around keratinocytes, which is known as the intercellular space (ICS) staining pattern—
representative of all pemphigus disease. In PF, this is a result of dsg-1-bound antibody on
the desmosomes at the keratinocyte cell surface. The intensity of this fluorescent stain in PF
may be greater in the upper epidermis due to the increased density of dsg-1 and subsequent
antibody deposition in the superficial epidermis (55). Complement component 3 (C3) may
also stain at the ICS in PF (56). PE may show staining of both the ICS and the basement
membrane zone (BMZ) (57).
Indirect Immunofluorescence
IIF is a staining technique that uses patient serum to identify antibodies directed against an
antigen on a specific type of tissue substrate. It has been found to have a sensitivity ranging
between 79–90% for diagnosing pemphigus disease (53). Human skin is commonly used as
substrate for IIF staining in patients suspected of having PF since it has been found to be
more sensitive (greater density of dsg-1) whereas monkey esophagus is preferentially used
to detect PV because of heightened sensitivity (greater density of dsg-3, the autoantigen
target of PV) (58,59). However, the use of both has been found to improve sensitivity to
100% (60). Like DIF, IIF will show ICS staining in PF with a potential greater fluorescent
intensity in the upper epidermis (Fig. 6) (61). IgG subclass staining for PF shows both IgG1
and IgG4 subclasses are produced against dsg-1, with IgG4 being the predominant
autoantibody subclass (62,63). IIF titers can be used as an approximate estimate of disease
activity in patients (64). For instance, patients with severe disease will typically have high
titers and patients with mild disease will have low titers. The direct correlation of disease
extent with the level of circulating IgG autoantibody as measured by IIF has been best
demonstrated by mouse models of pemphigus (65).
Enzyme-linked immunosorbent assay
ELISA studies have been found to be a sensitive and specific tool for pemphigus diagnosis.
This method uses purified recombinant human dsg-1 to detect PF IgG autoantibodies in
patient serum (66). ELISA also provides a quantitative way to measure the amount of
circulating autoantibodies (67), which can be used to monitor a patient’s response to
treatment. One study found that the sensitivity of diagnosing untreated cases of PF was
100% whereas in treated cases it was 92% (68). However, the negative cases could represent
a successful response to treatment. The threshold for a positive result in this study was
chosen to give a specificity of 98%. A larger study found the sensitivity and specificity of
detecting dsg-1 autoantibodies in PF patients to be 97.9% and 98.9%, respectively (69). In
endemic regions of FS, the specificity of ELISA is relatively lower since more normal
individuals in these areas test positive (increase in false positives) for total IgG anti-dsg-1
autoantibodies (11). However, a positive ELISA result for IgG4 anti-dsg-1 autoantibodies in
normal individuals from endemic areas can be used to predict those with preclinical FS who
could develop clinical manifestations in the future (70). Unlike the rough estimate of disease
severity that IIF provides in humans, ELISA titers have been found to consistently correlate
with disease activity throughout the patient’s clinical course (71,72,73,74). Therefore, it can
be considered the best laboratory analysis for monitoring a patient’s response to therapy.
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Intact blister filled with inflammatory exudate on left side of chest.
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Isolated scaly, erythematous plaque with peripheral erosion on left cheek.
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Disseminated papulosquamous eruption on back evolving from the preceding superficial
blisters and secondary erosions of PF.
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Biopsy of PF lesion. Subcorneal blister formation due to acantholysis of keratinocytes.
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Positive indirect immunofluorescent staining using PF patient serum on human skin
substrate. This staining pattern directed against the intercellular space (ICS) is characteristic
of pemphigus.
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Table 1
List of Drugs Associated with PF
ACE Inhibitors
   Captopril (75)
   Lisinopril (76)
   Enalapril (77)
   Fosinopril (78)
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
   Penicillamine
   Bucillamine (79)
Angiotensin-II Receptor Blockers (ARBs)
   Candesartan (80)
Antibiotics
   Rifampicin (81)
Orphan Drugs
   Tiopronin (82)
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